Connecticut 2019 Regular Session

Connecticut House Bill HB07174 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1
2	2
3		-	LCO \\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-R01-
4		-	HB.docx
5		-	1 of 10
	3	+	LCO No. 4454 1 of 10
6	4
7		-	General Assembly ~~Substitute~~ Bill No. 7174
	5	+	General Assembly Raised Bill No. 7174
8	6		January Session, 2019
	7	+	LCO No. 4454
9	8
10	9
	10	+	Referred to Committee on INSURANCE AND REAL ESTATE
11	11
	12	+
	13	+	Introduced by:
	14	+	(INS)
12	15
13	16
14	17		AN ACT CONCERNING PR ESCRIPTION DRUGS.
15	18		Be it enacted by the Senate and House of Representatives in General
16	19		Assembly convened:
17	20
18	21		Section 1. (NEW) (Effective October 1, 2019) (a) For the purposes of 1
19	22		this section: 2
20	23		(1) "Drug" has the same meaning as provided in section 21a-92 of 3
21	24		the general statutes; 4
22	25		(2) "Participating individual" means an individual resident of this 5
23	26		state who is participating in the program; 6
24	27		(3) "Participating pharmacist" means a pharmacist who is 7
25	28		participating in the program; 8
26	29		(4) "Participating pharmacy" means a pharmacy that is participating 9
27	30		in the program; 10
28	31		(5) "Pharmacist" has the same meaning as provided in section 38a-11
29	32		479aaa of the general statutes; 12
30	33		(6) "Pharmacy" has the same meaning as provided in section 38a-13
31		-	479aaa of the general statutes; 14
32		-	(7) "Pharmacy benefits manager" has the same meaning as provided 15
33		-	in section 38a-479aaa of the general statutes; 16 Substitute Bill No. 7174
	34	+	479aaa of the general statutes; 14 Raised Bill No. 7174
34	35
35	36
36		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-
37		-	R01-HB.docx }
38		-	2 of 10
39	37
	38	+	LCO No. 4454 2 of 10
	39	+
	40	+	(7) "Pharmacy benefits manager" has the same meaning as provided 15
	41	+	in section 38a-479aaa of the general statutes; 16
40	42		(8) "Program" means the Connecticut Prescription Drug Program 17
41	43		established by the Comptroller pursuant to subsection (b) of this 18
42	44		section; and 19
43	45		(9) "Program price" means the reimbursement rates and prescription 20
44	46		drug prices established under the program. 21
45	47		(b) The Comptroller shall, within available appropriations, establish 22
46	48		the Connecticut Prescription Drug Program. The purposes of the 23
47	49		program shall be to: (1) Purchase outpatient prescription drugs, 24
48	50		replenish supplies of outpatient prescription drugs or reimburse 25
49	51		participating pharmacies and participating pharmacists for outpatient 26
50	52		prescription drugs in order to secure the lowest possible prices and 27
51	53		greatest possible rebates for outpatient prescription drugs prescribed 28
52	54		to participating individuals; (2) make outpatient prescription drugs 29
53	55		available at the lowest possible cost to participating individuals; (3) 30
54	56		maintain a list of the most cost-effective and therapeutically effective 31
55	57		outpatient prescription drugs available to participating individuals; (4) 32
56	58		purchase and provide discounted outpatient prescription drugs to 33
57	59		participating individuals; and (5) coordinate a comprehensive 34
58	60		pharmacy benefit for participating individuals. 35
59	61		(c) (1) As part of the program, the Comptroller shall: (A) Establish 36
60	62		eligibility criteria for individual residents of this state, as well as 37
61	63		pharmacies and pharmacists, to participate in the program; (B) 38
62	64		prescribe an application form for (i) individual residents of this state to 39
63	65		become participating individuals, (ii) pharmacists to become 40
64	66		participating pharmacists, and (iii) pharmacies to become participating 41
65	67		pharmacies; (C) issue to participating individuals a prescription drug 42
66	68		identification card containing the information necessary for claims 43
67	69		processing; (D) establish a list of preferred outpatient prescription 44
68	70		drugs for the program; (E) negotiate with pharmaceutical 45
69		-	manufacturers and other persons to secure discounts and rebates for 46
	71	+	manufacturers and other persons to secure discounts and rebates for 46 Raised Bill No. 7174
	72	+
	73	+
	74	+
	75	+	LCO No. 4454 3 of 10
	76	+
70	77		outpatient prescription drugs; (F) establish program prices; (G) 47
71	78		adjudicate pharmacy claims and reimburse participating pharmacies 48
72		-	and participating pharmacists at program prices; (H) develop a system 49 Substitute Bill No. 7174
73		-
74		-
75		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-
76		-	R01-HB.docx }
77		-	3 of 10
78		-
	79	+	and participating pharmacists at program prices; (H) develop a system 49
79	80		for allocating and distributing the operational costs of the program, as 50
80	81		well as any rebates, to participating individuals; and (I) charge 51
81	82		administrative fees to participating individuals, participating 52
82	83		pharmacists and participating pharmacies to cover the operational 53
83	84		costs of the program, and deposit such fees in the account established 54
84	85		under section 2 of this act. 55
85	86		(2) As part of the program, the Comptroller may: (A) Purchase 56
86	87		outpatient prescription drugs on behalf of participating individuals; or 57
87	88		(B) cooperate with other states or regional consortia to purchase 58
88	89		outpatient prescription drugs on behalf of participating individuals. 59
89	90		(3) The Comptroller may enter into a contract with a pharmacy 60
90	91		benefits manager to perform the Comptroller's duties under 61
91	92		subdivisions (1) and (2) of this subsection, provided the Comptroller 62
92	93		shall require the pharmacy benefits manager to charge such pharmacy 63
93	94		benefits manager's lowest available rate to perform such duties. 64
94	95		(d) The Comptroller may adopt regulations, in accordance with 65
95	96		chapter 54 of the general statutes, to implement the provisions of this 66
96	97		section. 67
97	98		Sec. 2. (NEW) (Effective October 1, 2019) There is established an 68
98	99		account to be known as the "Connecticut prescription drug program 69
99	100		account" which shall be a separate, nonlapsing account within the 70
100	101		General Fund. The account shall contain any moneys required by law 71
101	102		to be deposited in the account. Moneys in the account shall be 72
102	103		expended by the Comptroller for the purposes of the Connecticut 73
103	104		Prescription Drug Program established pursuant to section 1 of this 74
104	105		act. 75
105	106		Sec. 3. (NEW) (Effective October 1, 2019) (a) Each pharmaceutical 76
106	107		manufacturer doing business in this state that manufactures a brand 77
107		-	name prescription drug and enters into an agreement with another 78
108		-	pharmaceutical manufacturer for the purpose of delaying or 79
109		-	preventing such other manufacturer from introducing a generic 80 Substitute Bill No. 7174
	108	+	name prescription drug and enters into an agreement with another 78 Raised Bill No. 7174
110	109
111	110
112		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-
113		-	R01-HB.docx }
114		-	4 of 10
115	111
	112	+	LCO No. 4454 4 of 10
	113	+
	114	+	pharmaceutical manufacturer for the purpose of delaying or 79
	115	+	preventing such other manufacturer from introducing a generic 80
116	116		substitute for such drug into the marketplace shall, not later than thirty 81
117	117		days after entering into such agreement, send notice to the Insurance 82
118	118		Commissioner, in a form and manner prescribed by the commissioner, 83
119	119		disclosing the name of such drug. 84
120	120		(b) (1) The commissioner shall, not later than thirty days after 85
121	121		receiving a notice pursuant to subsection (a) of this section, send notice 86
122	122		to each health carrier, as defined in section 38a-1080 of the general 87
123	123		statutes, and pharmacy benefits manager, as defined in section 38a-88
124	124		479aaa of the general statutes, doing business in this state. Such notice 89
125	125		shall, at a minimum: 90
126	126		(A) Disclose the name of the brand name prescription drug that is 91
127	127		the subject of the notice the commissioner received pursuant to 92
128	128		subsection (a) of this section; and 93
129	129		(B) Instruct such health carrier, if such health carrier includes such 94
130	130		drug on such health carrier's drug formulary or list of covered drugs, 95
131	131		or pharmacy benefits manager, if such pharmacy benefits manager 96
132	132		administers a prescription drug benefit that includes such drug, to 97
133	133		immediately reduce the cost of such drug to covered individuals by an 98
134	134		amount that is equal to fifty per cent of the manufacturer's wholesale 99
135	135		list price for such drug. 100
136		-	(2) For the purposes of this ~~subsection~~, "manufacturer's wholesale 101
	136	+	(2) For the purposes of this subdivision, "manufacturer's wholesale 101
137	137		list price" has the same meaning as provided in section 21a-126 of the 102
138	138		general statutes. 103
139	139		(c) The provisions of this section shall apply to the maximum extent 104
140	140		permitted by applicable law. 105
141	141		(d) The commissioner may adopt regulations, in accordance with 106
142	142		chapter 54 of the general statutes, to implement the provisions of this 107
143		-	section. 108
144		-	Sec. 4. Subdivision (3) of subsection (m) of section 5-259 of the 109
145		-	general statutes is repealed and the following is substituted in lieu 110 Substitute Bill No. 7174
	143	+	section. 108 Raised Bill No. 7174
146	144
147	145
148		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-
149		-	R01-HB.docx }
150		-	5 of 10
151	146
	147	+	LCO No. 4454 5 of 10
	148	+
	149	+	Sec. 4. Subdivision (3) of subsection (m) of section 5-259 of the 109
	150	+	general statutes is repealed and the following is substituted in lieu 110
152	151		thereof (Effective October 1, 2019): 111
153	152		(3) (A) [(i)] For the purposes of this subdivision: 112
154	153		(i) "Nonstate public employer" means (I) a municipality or other 113
155	154		political subdivision of the state, including a board of education, quasi-114
156	155		public agency or public library, as defined in section 11-24a, or (II) the 115
157	156		Teachers' Retirement Board; and 116
158	157		(ii) "Qualified private employer" means a self-insured private 117
159	158		employer doing business in this state. 118
160	159		(B) The Comptroller shall offer nonstate public employers and 119
161	160		qualified private employers the option to purchase prescription drugs 120
162	161		for their employees, employees' dependents and retirees under the 121
163	162		purchasing authority of the state pursuant to section 1 of public act 09-122
164	163		206, subject to the provisions of subparagraph [(E)] (F) of this 123
165		-	subdivision. 124
166		-	[(ii) ~~For purposes~~ of ~~this subdivision, "nonstate public employer"~~ 125
167		-	~~means (I)~~ a ~~municipality~~ or ~~other political subdivision of the state,~~ 126
168		-	~~including a board of education~~, ~~quasi-public agency~~ or ~~public library,~~ 127
169		-	~~as defined in section 11-24a, or (II) the Teachers' Retirement~~ Board.] 128
	164	+	subdivision. [(ii) For purposes of this subdivision, "nonstate public 124
	165	+	employer" means (I) a municipality or other political subdivision of the 125
	166	+	state, including a board of education, quasi-public agency or public 126
	167	+	library, as defined in section 11-24a, or (II) the Teachers' Retirement 127
	168	+	Board.] 128
170	169		[(B)] (C) The Comptroller shall establish procedures to determine (i) 129
171	170		the eligibility requirements for, (ii) the enrollment procedures for, (iii) 130
172	171		the duration of, (iv) requirements regarding payment for, and (v) the 131
173	172		procedures for withdrawal from and termination of, the purchasing of 132
174	173		prescription drugs for nonstate public employers and qualified private 133
175	174		employers under subparagraph [(A)] (B) of this subdivision. 134
176	175		[(C)] (D) The Comptroller may offer to nonstate public employers 135
177	176		and qualified private employers that choose to purchase prescription 136
178	177		drugs pursuant to subparagraph [(A)] (B) of this subdivision the 137
179	178		option to purchase stop loss coverage from an insurer at a rate 138
180		-	negotiated by the Comptroller. 139 ~~Substitute~~ Bill No. 7174
	179	+	negotiated by the Comptroller. 139 Raised Bill No. 7174
181	180
182	181
183		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-
184		-	R01-HB.docx }
185		-	6 of 10
	182	+
	183	+	LCO No. 4454 6 of 10
186	184
187	185		[(D)] (E) Two or more nonstate public employers or qualified 140
188	186		private employers may join together for the purpose of purchasing 141
189	187		prescription drugs for their employees, employees' dependents and 142
190	188		retirees. Such arrangement shall not constitute a multiple employer 143
191	189		welfare arrangement, as defined in Section 3 of the Employee 144
192	190		Retirement Income Security Act of 1974, as amended from time to 145
193	191		time. 146
194	192		[(E)] (F) (i) The Comptroller shall offer nonstate public employers 147
195	193		and qualified private employers the option to purchase prescription 148
196	194		drugs through the plan set forth in the State Employees' Bargaining 149
197	195		Agent Coalition's collective bargaining agreement with the state only if 150
198	196		the Health Care Cost Containment Committee, established in 151
199	197		accordance with the ratified agreement between the state and said 152
200	198		coalition pursuant to subsection (f) of section 5-278, has indicated in 153
201	199		writing to the Comptroller that allowing such nonstate public 154
202	200		employers and qualified private employers such option is consistent 155
203	201		with said coalition's collective bargaining agreement. 156
204	202		(ii) Such writing shall not be required if the Comptroller establishes 157
205	203		a separate prescription drugs purchasing plan or plans for nonstate 158
206	204		public employers and qualified private employers. 159
207	205		(iii) Nonstate public employers and qualified private employers that 160
208	206		purchase prescription drugs pursuant to this subdivision shall pay the 161
209	207		full cost of their own claims and prescription drugs. 162
210	208		Sec. 5. Section 38a-477cc of the general statutes is repealed and the 163
211	209		following is substituted in lieu thereof (Effective October 1, 2019): 164
212	210		(a) [On and after January 1, 2018, no] No contract for pharmacy 165
213	211		services entered into in the state between a health carrier, as defined in 166
214	212		section 38a-591a, or pharmacy benefits manager, as defined in section 167
215	213		38a-479aaa, and a pharmacy or pharmacist shall: 168
216	214		(1) On and after January 1, 2018, contain a provision prohibiting or 169
217		-	penalizing, including through increased utilization review, reduced 170 ~~Substitute~~ Bill No. 7174
	215	+	penalizing, including through increased utilization review, reduced 170 Raised Bill No. 7174
218	216
219	217
220		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-
221		-	R01-HB.docx }
222		-	7 of 10
	218	+
	219	+	LCO No. 4454 7 of 10
223	220
224	221		payments or other financial disincentives, a pharmacist's disclosure to 171
225	222		an individual purchasing prescription medication of information 172
226		-	regarding: [(1) the] (A) The cost of the prescription medication to the 173
227		-	individual; [,] or [(2) the] (B) The availability of any therapeutically 174
228		-	equivalent alternative medications or alternative methods of 175
229		-	purchasing the prescription medication, including, but not limited to, 176
230		-	paying a cash price, that are less expensive than the cost of the 177
231		-	prescription medication to the individual; [.] and 178
232		-	(2) On and after January 1, 2020, contain a provision permitting the 179
233		-	health carrier or pharmacy benefits manager to recoup, directly or 180
234		-	indirectly, from a pharmacy or pharmacist any portion of a claim that 181
235		-	such health carrier or pharmacy benefits manager has paid to the 182
236		-	pharmacy or pharmacist, unless such recoupment is permitted under 183
237		-	section 38a-479iii or required by applicable law. 184
238		-	(b) (1) On and after January 1, 2018, no health carrier or pharmacy 185
239		-	benefits manager shall require an individual to make a payment at the 186
240		-	point of sale for a covered prescription medication in an amount 187
241		-	greater than the lesser of: 188
242		-	[(1) the] (A) The applicable copayment for such prescription 189
243		-	medication; [, (2) the] (B) The allowable claim amount for the 190
244		-	prescription medication; [,] or [(3) the] (C) The amount an individual 191
245		-	would pay for the prescription medication if the individual purchased 192
246		-	the prescription medication without using a health benefit plan, as 193
247		-	defined in section 38a-591a, or any other source of prescription 194
248		-	medication benefits or discounts. 195
249		-	(2) For the purposes of this subsection, "allowable claim amount" 196
250		-	means the amount the health carrier or pharmacy benefits manager 197
251		-	has agreed to pay the pharmacy for the prescription medication. 198
252		-	(c) Any provision of a contract that violates the provisions of this 199
253		-	section shall be void and unenforceable. Any general business practice 200
254		-	that violates the provisions of this section shall constitute an unfair 201 Substitute Bill No. 7174
	223	+	regarding: 173
	224	+	[(1) the] (A) The cost of the prescription medication to the 174
	225	+	individual; [,] or 175
	226	+	[(2) the] (B) The availability of any therapeutically equivalent 176
	227	+	alternative medications or alternative methods of purchasing the 177
	228	+	prescription medication, including, but not limited to, paying a cash 178
	229	+	price, that are less expensive than the cost of the prescription 179
	230	+	medication to the individual; [.] and 180
	231	+	(2) On and after January 1, 2020, contain a provision permitting the 181
	232	+	health carrier or pharmacy benefits manager to recoup, directly or 182
	233	+	indirectly, from a pharmacy or pharmacist any portion of a claim that 183
	234	+	such health carrier or pharmacy benefits manager has paid to the 184
	235	+	pharmacy or pharmacist, unless such recoupment is permitted under 185
	236	+	section 38a-479iii or required by applicable law. 186
	237	+	(b) (1) On and after January 1, 2018, no health carrier or pharmacy 187
	238	+	benefits manager shall require an individual to make a payment at the 188
	239	+	point of sale for a covered prescription medication in an amount 189
	240	+	greater than the lesser of: 190
	241	+	[(1) the] (A) The applicable copayment for such prescription 191
	242	+	medication; [,] 192
	243	+	[(2) the] (B) The allowable claim amount for the prescription 193
	244	+	medication; [,] or 194
	245	+	[(3) the] (C) The amount an individual would pay for the 195
	246	+	prescription medication if the individual purchased the prescription 196
	247	+	medication without using a health benefit plan, as defined in section 197
	248	+	38a-591a, or any other source of prescription medication benefits or 198
	249	+	discounts. 199
	250	+	(2) For the purposes of this subsection, "allowable claim amount" 200 Raised Bill No. 7174
255	251
256	252
257		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-
258		-	R01-HB.docx }
259		-	8 of 10
260	253
261		-	trade practice pursuant to chapter 735a. The inva lidity or 202
262		-	unenforceability of any contract provision under this subsection shall 203
263		-	not affect any other provision of the contract. 204
264		-	(d) The Insurance Commissioner may: [, (1) pursuant to the 205
265		-	provisions of chapter 697, enforce] 206
266		-	(1) Enforce the provisions of this section [,] pursuant to chapter 697; 207
267		-	and 208
268		-	(2) [upon] Upon request, audit a contract for pharmacy services for 209
269		-	compliance with the provisions of this section. 210
270		-	Sec. 6. (Effective from passage) (a) There is established a task force to 211
271		-	study drug reimportation. Such study shall include, but need not be 212
272		-	limited to, an examination of the feasibility of implementing a drug 213
273		-	reimportation program for the purpose of lowering the cost of 214
274		-	prescription drugs and health insurance in this state. 215
275		-	(b) The task force shall consist of the following members: 216
276		-	(1) Two appointed by the speaker of the House of Representatives; 217
277		-	(2) Two appointed by the president pro tempore of the Senate; 218
278		-	(3) One appointed by the majority leader of the House of 219
279		-	Representatives; 220
280		-	(4) One appointed by the majority leader of the Senate; 221
281		-	(5) One appointed by the minority leader of the House of 222
282		-	Representatives; 223
283		-	(6) One appointed by the minority leader of the Senate; 224
284		-	(7) The Attorney General, or the Attorney General's designee; 225
285		-	(8) The Comptroller, or the Comptroller's designee; 226 Substitute Bill No. 7174
	254	+	LCO No. 4454 8 of 10
	255	+
	256	+	means the amount the health carrier or pharmacy benefits manager 201
	257	+	has agreed to pay the pharmacy for the prescription medication. 202
	258	+	(c) Any provision of a contract that violates the provisions of this 203
	259	+	section shall be void and unenforceable. Any general business practice 204
	260	+	that violates the provisions of this section shall constitute an unfair 205
	261	+	trade practice pursuant to chapter 735a. The invalidity or 206
	262	+	unenforceability of any contract provision under this subsection shall 207
	263	+	not affect any other provision of the contract. 208
	264	+	(d) The Insurance Commissioner may: [, (1) pursuant to the 209
	265	+	provisions of chapter 697, enforce] 210
	266	+	(1) Enforce the provisions of this section [,] pursuant to chapter 697; 211
	267	+	and 212
	268	+	(2) [upon] Upon request, audit a contract for pharmacy services for 213
	269	+	compliance with the provisions of this section. 214
	270	+	Sec. 6. (Effective from passage) (a) There is established a task force to 215
	271	+	study drug reimportation. Such study shall include, but need not be 216
	272	+	limited to, an examination of the feasibility of implementing a drug 217
	273	+	reimportation program for the purpose of lowering the cost of 218
	274	+	prescription drugs and health insurance in this state. 219
	275	+	(b) The task force shall consist of the following members: 220
	276	+	(1) Two appointed by the speaker of the House of Representatives; 221
	277	+	(2) Two appointed by the president pro tempore of the Senate; 222
	278	+	(3) One appointed by the majority leader of the House of 223
	279	+	Representatives; 224
	280	+	(4) One appointed by the majority leader of the Senate; 225
	281	+	(5) One appointed by the minority leader of the House of 226
	282	+	Representatives; 227 Raised Bill No. 7174
286	283
287	284
288		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-
289		-	R01-HB.docx }
290		-	9 of 10
291	285
292		-	(9) The Insurance Commissioner, or the commissioner's designee; 227
293		-	(10) The Commissioner of Public Health, or the commissioner's 228
294		-	designee; 229
295		-	(11) The Commissioner of Social Services, or the commissioner's 230
296		-	designee; 231
297		-	(12) The executive director of the Office of Health Strategy, or the 232
298		-	executive director's designee; 233
299		-	(13) The Healthcare Advocate, or the Healthcare Advocate's 234
300		-	designee; and 235
301		-	(14) Two persons appointed by the Governor. 236
302		-	(c) Any member of the task force appointed under subdivision (1), 237
303		-	(2), (3), (4), (5) or (6) of subsection (b) of this section may be a member 238
304		-	of the General Assembly. 239
305		-	(d) All appointments to the task force shall be made not later than 240
306		-	thirty days after the effective date of this section. Any vacancy shall be 241
307		-	filled by the appointing authority. 242
308		-	(e) The speaker of the House of Representatives and the president 243
309		-	pro tempore of the Senate shall select the chairpersons of the task force 244
310		-	from among the members of the task force. Such chairpersons shall 245
311		-	schedule the first meeting of the task force, which shall be held not 246
312		-	later than sixty days after the effective date of this section. 247
313		-	(f) The administrative staff of the joint standing committee of the 248
314		-	General Assembly having cognizance of matters relating to insurance 249
315		-	shall serve as administrative staff of the task force. 250
316		-	(g) Not later than January 1, 2020, the task force shall submit a 251
317		-	report on its findings and recommendations to the joint standing 252
318		-	committee of the General Assembly having cognizance of matters 253
319		-	relating to insurance, in accordance with the provisions of section 11-254 Substitute Bill No. 7174
	286	+	LCO No. 4454 9 of 10
	287	+
	288	+	(6) One appointed by the minority leader of the Senate; 228
	289	+	(7) The Attorney General, or the Attorney General's designee; 229
	290	+	(8) The Comptroller, or the Comptroller's designee; 230
	291	+	(9) The Insurance Commissioner, or the commissioner's designee; 231
	292	+	(10) The Commissioner of Public Health, or the commissioner's 232
	293	+	designee; 233
	294	+	(11) The Commissioner of Social Services, or the commissioner's 234
	295	+	designee; 235
	296	+	(12) The executive director of the Office of Health Strategy, or the 236
	297	+	executive director's designee; 237
	298	+	(13) The Healthcare Advocate, or the Healthcare Advocate's 238
	299	+	designee; and 239
	300	+	(14) Two persons appointed by the Governor. 240
	301	+	(c) Any member of the task force appointed under subdivision (1), 241
	302	+	(2), (3), (4), (5) or (6) of subsection (b) of this section may be a member 242
	303	+	of the General Assembly. 243
	304	+	(d) All appointments to the task force shall be made not later than 244
	305	+	thirty days after the effective date of this section. Any vacancy shall be 245
	306	+	filled by the appointing authority. 246
	307	+	(e) The speaker of the House of Representatives and the president 247
	308	+	pro tempore of the Senate shall select the chairpersons of the task force 248
	309	+	from among the members of the task force. Such chairpersons shall 249
	310	+	schedule the first meeting of the task force, which shall be held not 250
	311	+	later than sixty days after the effective date of this section. 251
	312	+	(f) The administrative staff of the joint standing committee of the 252
	313	+	General Assembly having cognizance of matters relating to insurance 253
	314	+	shall serve as administrative staff of the task force. 254 Raised Bill No. 7174
320	315
321	316
322		-	LCO {\\PRDFS1\HCOUSERS\BARRYJN\WS\2019HB-07174-
323		-	R01-HB.docx }
324		-	10 of 10
325	317
326		-	4a of the general statutes. The task force shall terminate on the date 255
327		-	that it submits such report or January 1, 2020, whichever is later. 256
	318	+	LCO No. 4454 10 of 10
	319	+
	320	+	(g) Not later than January 1, 2020, the task force shall submit a 255
	321	+	report on its findings and recommendations to the joint standing 256
	322	+	committee of the General Assembly having cognizance of matters 257
	323	+	relating to insurance, in accordance with the provisions of section 11-258
	324	+	4a of the general statutes. The task force shall terminate on the date 259
	325	+	that it submits such report or January 1, 2020, whichever is later.260
328	326		This act shall take effect as follows and shall amend the following
329	327		sections:
330	328
331	329		Section 1 October 1, 2019 New section
332	330		Sec. 2 October 1, 2019 New section
333	331		Sec. 3 October 1, 2019 New section
334	332		Sec. 4 October 1, 2019 5-259(m)(3)
335	333		Sec. 5 October 1, 2019 38a-477cc
336	334		Sec. 6 from passage New section
337	335
338		-	Statement of Legislative Commissioners:
339		-	In Section 3(b)(2), "subdivision" was changed to "subsection" for
340		-	accuracy.
341		-
342		-	INS Joint Favorable Subst. -LCO
	336	+	Statement of Purpose:
	337	+	To: (1) Establish the "Connecticut Prescription Drug Program" and the
	338	+	"Connecticut prescription drug program account"; (2) require
	339	+	pharmaceutical manufacturers to send notice to the Insurance
	340	+	Commissioner regarding "pay-for-delay" agreements, and require
	341	+	health carriers and pharmacy benefits managers to reduce the cost of
	342	+	brand name prescription drugs that are the subject of such agreements;
	343	+	(3) require the Comptroller to offer qualified private employers the
	344	+	option to purchase prescription drugs for their employees, employees'
	345	+	dependents and retirees through the Comptroller's purchasing
	346	+	authority; (4) prohibit any health carrier or pharmacy benefits manager
	347	+	from recouping any portion of a claim that such carrier or manager has
	348	+	paid to a pharmacy or pharmacist; and (5) establish a task force to
	349	+	study drug reimportation.
	350	+	[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline,
	351	+	except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is
	352	+	not underlined.]
343	353